US20050112175A1 - Drug delivery device - Google Patents

Drug delivery device Download PDF

Info

Publication number
US20050112175A1
US20050112175A1 US10/957,910 US95791004A US2005112175A1 US 20050112175 A1 US20050112175 A1 US 20050112175A1 US 95791004 A US95791004 A US 95791004A US 2005112175 A1 US2005112175 A1 US 2005112175A1
Authority
US
United States
Prior art keywords
drug delivery
pharmaceutically active
inner core
delivery device
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/957,910
Inventor
Yoseph Yaacobi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Priority to US10/957,910 priority Critical patent/US20050112175A1/en
Publication of US20050112175A1 publication Critical patent/US20050112175A1/en
Assigned to ALCON, INC. reassignment ALCON, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: ALCON UNIVERSAL LTD.
Priority to US11/567,892 priority patent/US7943162B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/14Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007Methods or devices for eye surgery
    • A61F9/00781Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007Methods or devices for eye surgery
    • A61F9/008Methods or devices for eye surgery using laser
    • A61F2009/00885Methods or devices for eye surgery using laser for treating a particular disease
    • A61F2009/00891Glaucoma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067Means for introducing or releasing pharmaceutical products into the body

Definitions

  • the present invention generally pertains to biocompatible implants for localized delivery of pharmaceutically active agents to body tissue. More particularly, but not by way of limitation, the present invention pertains to biocompatible implants for localized delivery of pharmaceutically active agents to the posterior segment of the eye.
  • Age related macular degeneration choroidal neovascularization (CNV), retinopathies (i.e. diabetic retinopathy, vitreoretinopathy), retinitis (i.e. cytomegalovirus (CMV) retinitis), uveitis, macular edema, and glaucoma are several examples.
  • AMD Age related macular degeneration
  • CNV choroidal neovascularization
  • retinopathies i.e. diabetic retinopathy, vitreoretinopathy
  • retinitis i.e. cytomegalovirus (CMV) retinitis
  • uveitis macular edema
  • macular edema glaucoma
  • Age related macular degeneration is the leading cause of blindness in the elderly. ARMD attacks the center of vision and blurs it, making reading, driving, and other detailed tasks difficult or impossible. About 200,000 new cases of ARMD occur each year in the United States alone. Current estimates reveal that approximately forty percent of the population over age 75 , and approximately twenty percent of the population over age 60 , suffer from some degree of macular degeneration. “Wet” ARMD is the type of ARMD that most often causes blindness. In wet ARMD, newly formed choroidal blood vessels (choroidal neovascularization (CNV)) leak fluid and cause progressive damage to the retina.
  • CNV choroidal neovascularization
  • CNV in ARMD two main methods of treatment are currently being developed, (a) photocoagulation and (b) the use of angiogenesis inhibitors.
  • photocoagulation can be harmful to the retina and is impractical when the CNV is near the fovea.
  • photocoagulation often results in recurrent CNV over time.
  • Oral or parenteral (non-ocular) administration of anti-angiogenic compounds is also being tested as a systemic treatment for ARMD.
  • systemic administration usually provides sub-therapeutic drug levels to the eye. Therefore, to achieve effective intraocular drug concentrations, either an unacceptably high dose or repetitive conventional doses are required.
  • Periocular injections of these compounds often result in the drug being quickly washed out and depleted from the eye, via periocular vasculature and soft tissue, into the general circulation. Repetitive intraocular injections may result in severe, often blinding, complications such as retinal detachment and endophthalmitis.
  • U.S. Pat. No. 5,824,072 to Wong discloses a non-biodegradable polymeric implant with a pharmaceutically active agent disposed therein.
  • the pharmaceutically active agent diffuses through the polymer body of the implant into the target tissue.
  • the pharmaceutically active agent may include drugs for the treatment of macular degeneration and diabetic retinopathy.
  • the implant is placed substantially within the tear fluid upon the outer surface of the eye over an avascular region, and may be anchored in the conjunctiva or sclera; episclerally or intrasclerally over an avascular region; substantially within the suprachoroidial space over an avascular region such as the pars plana or a surgically induced avascular region; or in direct communication with the vitreous.
  • U.S. Pat. No. 5,476,511 to Gwon et al. discloses a polymer implant for placement under the conjunctiva of the eye.
  • the implant may be used to deliver neovascular inhibitors for the treatment of ARMD and drugs for the treatment of retinopathies, retinitis, and CMV retinitis.
  • the pharmaceutically active agent diffuses through the polymer body of the implant.
  • U.S. Pat. No. 5,773,019 to Ashton et al. discloses a non-bioerodable polymer implant for delivery of certain drugs including angiostatic steroids and drugs such as cyclosporine for the treatment of uveitis. Once again, the pharmaceutically active agent diffuses through the polymer body of the implant.
  • implants require careful design and manufacture to permit controlled diffusion of the pharmaceutically active agent through a polymer body (matrix devices) or polymer membrane (reservoir devices) to the desired site of therapy. Drug release from these devices depends on the porosity and diffusion characteristics of the matrix or membrane, respectively. These parameters must be tailored for each drug moiety to be used with these devices. Consequently, these requirements generally increase the complexity and cost of such implants.
  • U.S. Pat. No. 5,824,073 to Peyman discloses an indentor for positioning in the eye.
  • the indentor has a raised portion that is used to indent or apply pressure to the sclera over the macular area of the eye.
  • This patent discloses that such pressure decreases choroidal congestion and blood flow through the subretinal neovascular membrane, which, in turn, decreases bleeding and subretinal fluid accumulation.
  • the surgical procedure for implanting such a device should be safe, simple, quick, and capable of being performed in an outpatient setting.
  • such a device should be easy and economical to manufacture.
  • such an implant should be capable of use in clinical studies to deliver various agents that create a specific physical condition in a patient or animal subject.
  • such an implantable drug delivery device is especially needed for localized delivery of pharmaceutically active agents to the posterior segment of the eye to combat ARMD, CNV, retinopathies, retinitis, uveitis, macular edema, and glaucoma.
  • One aspect of the present invention comprises a drug delivery device including a body having an internal surface for placement proximate a target tissue and a well having an opening to the internal surface.
  • An inner core comprising a pharmaceutically active agent is disposed in the well.
  • the present invention comprises a method of delivering a pharmaceutically active agent to a target tissue within a body.
  • a drug delivery device is provided.
  • the drug delivery device includes a body having an internal surface and a well having an opening to the internal surface, and an inner core disposed in the well comprising a pharmaceutically active agent.
  • the device is disposed within the body so that the pharmaceutically active agent is in communication with the target tissue through the opening.
  • the present invention comprises an ophthalmic drug delivery device including a body having a scleral surface for placement proximate a sclera and a well or cavity having an opening to the scleral surface.
  • An inner core comprising a pharmaceutically active agent is disposed in the well.
  • the present invention comprises a method of delivering a pharmaceutically active agent to an eye having a sclera.
  • a drug delivery device is provided.
  • the drug delivery device includes a body having a scleral surface and a well having an opening to the scleral surface, and an inner core disposed in the well comprising a pharmaceutically active agent.
  • the device is disposed within the eye so that the pharmaceutically active agent is in communication with the sclera through the opening.
  • the present invention comprises a method of delivering a pharmaceutically active agent to an eye having a sclera, a Tenon's capsule, and a macula.
  • a drug delivery device comprising a body having a pharmaceutically active agent disposed therein is provided. The device is disposed on an outer surface of the sclera, below the Tenon's capsule, and proximate the macula.
  • FIG. 1 is a side sectional view of a drug delivery device according to a preferred embodiment of the present invention
  • FIG. 2 is a side sectional view of a second drug delivery device according to a preferred embodiment of the present invention.
  • FIG. 3 is a side sectional view schematically illustrating the human eye
  • FIG. 4 is detailed cross-sectional view of the eye of FIG. 3 along line 4 - 4 ;
  • FIG. 5 is a perspective view of an ophthalmic drug delivery device according to a preferred embodiment of the present invention.
  • FIG. 6A is a side sectional view of the ophthalmic drug delivery device of FIG. 5 ;
  • FIG. 6B is an enlarged cross-sectional view of the ophthalmic drug delivery device of FIG. 6A taken along line 6 B- 6 B;
  • FIG. 7 is a graphical illustration of the results of a pharmacokinetic study with New Zealand White rabbits implanted with the ophthalmic drug delivery device of FIGS. 5 through 6 B showing the mean concentration of a pharmaceutically active agent at a target site in the retina and choroid of the rabbits as a function of time.
  • FIGS. 1 through 7 of the drawings like numerals being used for like and corresponding parts of the various drawings.
  • FIG. 1 schematically illustrates a drug delivery device 10 according to a preferred embodiment of the present invention.
  • Device 10 may be used in any case where localized delivery of a pharmaceutically active agent to body tissue is required.
  • device 10 may be used to treat a medical disorder of the eye, ear, nose, throat, skin, subcutaneous tissue, or bone.
  • Device 10 may be used in humans or animals.
  • Device 10 generally includes a body 12 having an internal surface 14 and an external surface 16 .
  • body 12 preferably has a generally rectangular three-dimensional geometry with a proximal end 18 and a distal end 20 .
  • Body 12 may have any other geometry that has an internal surface 14 for placement proximate a target tissue in the body of a patient.
  • body 12 may have a cylindrical, an oval, a square, or other polygonal three-dimensional geometry.
  • Body 12 includes a well or cavity 22 having an opening 24 to internal surface 14 .
  • An inner core 26 is preferably disposed in well 22 .
  • Inner core 26 is preferably a tablet comprising one or more pharmaceutically active agents.
  • inner core 26 may comprise a conventional hydrogel having one or more pharmaceutically active agents disposed therein.
  • a retaining member 28 is preferably disposed proximate opening 24 . Retaining member 28 prevents inner core 26 from falling out of well 22 .
  • retaining member 28 is preferably a continuous rim or lip disposed circumferentially around opening 24 having a diameter slightly less than the diameter of tablet 26 .
  • retaining member 26 may comprise one or more members that extend from body 12 into opening 24 .
  • inner core 26 may alternatively comprise a suspension, solution, powder, or combination thereof containing one or more pharmaceutically active agents.
  • internal surface 14 is formed without opening 24 , and the suspension, solution, powder, or combination thereof diffuses through the relatively thin portion of internal surface 14 below inner core 26 .
  • device 10 may be formed without well 22 or inner core 26 , and the pharmaceutically active agent(s) in the form of a suspension, solution, powder, or combination thereof may be dispersed throughout body 12 of device 10 .
  • the pharmaceutically active agent diffuses through body 12 into the target tissue.
  • the geometry of device 10 maximizes communication between the pharmaceutically active agent of inner core 26 and the tissue underlying internal surface 14 .
  • Internal surface 14 preferably physically contacts the target tissue.
  • the target tissue has a generally flat surface
  • device 10 would be appropriate for the delivery of a pharmaceutically active agent.
  • a device 10 a shown in FIG. 2 having a generally concave internal surface 14 a designed to mate with such a target surface may be utilized. Corners 30 of proximal end 18 a , and corners 32 of distal end 20 a , may be slanted and/or rounded off to facilitate surgical placement of device 10 a and to maximize comfort to the patient.
  • Retaining member 28 is preferably designed with a minimum thickness necessary to retain inner core 26 so as to dispose a surface 26 a of inner core 26 in close proximity to the target tissue.
  • inner core 26 may be formed so that surface 26 a physically contacts the target tissue.
  • device 10 or 10 a may be disposed in the body of a patient so that internal surface 14 or 14 a is disposed proximate the target tissue.
  • internal surface 14 or 14 a physically contacts intermediate tissue disposed between it and the target tissue.
  • the pharmaceutically active agent of inner core 26 communicates with the target tissue through opening 24 and this intermediate tissue.
  • body 12 preferably comprises a biocompatible, non-bioerodable material.
  • Body 12 more preferably comprises a biocompatible, non-bioerodable polymeric composition.
  • Said polymeric composition may be a homopolymer, a copolymer, straight, branched, cross-linked, or a blend.
  • polymers suitable for use in said polymeric composition include silicone, polyvinyl alcohol, ethylene vinyl acetate, polylactic acid, nylon, polypropylene, polycarbonate, cellulose, cellulose acetate, polyglycolic acid, polylactic-glycolic acid, cellulose esters, polyethersulfone, acrylics, their derivatives, and combinations thereof.
  • suitable soft acrylics are more fully disclosed in U.S. Pat.
  • Said polymeric composition most preferably comprises silicone.
  • said polymeric composition may also comprise other conventional materials that affect its physical properties, including, but not limited to, porosity, tortuosity, permeability, rigidity, hardness, and smoothness. Exemplary materials affecting certain ones of these physical properties include conventional plasticizers, fillers, and lubricants.
  • Said polymeric composition may comprise other conventional materials that affect its chemical properties, including, but not limited to, toxicity, hydrophobicity, and body 12 —inner core 26 interaction. Body 12 is preferably impermeable to the pharmaceutically active agent of inner core 26 .
  • the diameter of well 22 may be slightly less than the diameter of inner core 26 . This frictional fit secures inner core 26 within well 22 .
  • body 12 may be formed without retaining member 28 , if desired.
  • Inner core 26 may comprise any pharmaceutically active agents suitable for localized delivery to a target tissue.
  • pharmaceutically active agents suitable for inner core 26 are anti-infectives, including, without limitation, antibiotics, antivirals, and antifungals; antiallergenic agents and mast cell stabilizers; steroidal and non-steroidal anti-inflammatory agents; combinations of anti-infective and anti-inflammatory agents; decongestants; anti-glaucoma agents, including, without limitation, adrenergics, ⁇ -adrenergic blocking agents, ⁇ -adrenergic agonists, parasypathomimetic agents, cholinesterase inhibitors, carbonic anhydrase inhibitors, and prostaglandins; combinations of anti-glaucoma agents; antioxidants; nutritional supplements; drugs for the treatment of cystoid macular edema including, without limitation, non-steroidal anti-inflammatory agents; drugs for the treatment of ARMD, including, without limitation, angiogenesis inhibitors and nutritional supplements; drugs for the treatment of herpetic infections
  • angiostatic steroids are more fully disclosed in U.S. Pat. Nos. 5,679,666 and 5,770,592, which are incorporated herein in their entirety by reference.
  • Preferred ones of such angiostatic steroids include 4,9(11)-Pregnadien-17 ⁇ ,21-diol-3,20-dione and 4,9(11)-Pregnadien-17 ⁇ ,21-diol-3,20-dione-21-acetate.
  • Inner core 26 may also comprise conventional non-active excipients to enhance the stability, solubility, penetrability, or other properties of the active agent or the drug core.
  • inner core 26 is a tablet, it may further comprise conventional excipients necessary for tableting, such as fillers and lubricants. Such tablets may be produced using conventional tableting methods.
  • the pharmaceutically active agent is preferably distributed evenly throughout the tablet.
  • inner core 26 may comprise a special tablet that bioerodes at a controlled rate, releasing the pharmaceutically active agent. By way of example, such bioerosion may occur through hydrolosis or enzymatic cleavage.
  • inner core 26 is a hydrogel, the hydrogel may bioerode at a controlled rate, releasing the pharmaceutically active agent. Alternatively, the hydrogel may be non-bioerodable but allow diffusion of the pharmaceutically active agent.
  • Device 10 may be made by conventional polymer processing methods, including, but not limited to, injection molding, extrusion molding, transfer molding, and compression molding. Preferably, device 10 is formed using conventional injection molding techniques. Inner core 26 is preferably disposed in well 22 after the formation of body 12 of device 10 . Retaining member 28 is preferably resilient enough to allow inner core 26 to be inserted through opening 24 and then to return to its position as shown in FIG. 1 .
  • Device 10 is preferably surgically placed proximate a target tissue.
  • the surgeon first makes an incision proximate the target tissue.
  • the surgeon performs a blunt dissection to a level at or near the target tissue.
  • the surgeon uses forceps to hold device 10 with internal surface 14 facing the target tissue and distal end 20 away from the surgeon.
  • the surgeon then introduces device 10 into the dissection tunnel, and positions device 10 with internal surface 14 facing the target tissue.
  • the surgeon may or may not use sutures to fix device 10 to the underlying tissue, depending on the specific tissue.
  • the surgeon sutures the opening and places a strip of antibiotic ointment on the surgical wound.
  • body 12 facilitates the unidirectional delivery of a pharmaceutically effective amount of the pharmaceutically active agent from inner core 26 to the target tissue.
  • body 12 including the geometry of internal surface 14 , well 22 , opening 24 , and retaining member 28 , facilitate the unidirectional delivery of a pharmaceutically effective amount of the pharmaceutically active agent from inner core 26 to the target tissue.
  • the absence of a polymer layer or membrane between inner core 26 and the underlying tissue greatly enhances and simplifies the delivery of an active agent to the target tissue.
  • Device 10 can be used to deliver a pharmaceutically effective amount of a pharmaceutically active agent to target tissue for many years, depending on the particular physicochemical properties of the pharmaceutically active agent employed. Important physicochemical properties include hydrophobicity, solubility, dissolution rate, diffusion coefficient, and tissue affinity. After inner core 26 no longer contains active agent, a surgeon may easily remove device 10 . In addition, the “preformed” tunnel facilitates the replacement of an old device 10 with a new device 10 .
  • FIGS. 3 through 6 B schematically illustrate an ophthalmic drug delivery device 50 according to a preferred embodiment of the present invention.
  • Device 50 may be used in any case where localized delivery of a pharmaceutically active agent to the eye is required.
  • Device 50 is particularly useful for localized delivery of active agents to the posterior segment of the eye.
  • a preferred use for device 50 is the delivery of pharmaceutically active agents to the retina proximate the macula for treating ARMD, choroidial neovascularization (CNV), retinopathies, retinitis, uveitis, macular edema, and glaucoma.
  • CNV choroidial neovascularization
  • retinopathies retinitis
  • uveitis macular edema
  • glaucoma glaucoma
  • device 50 may also be utilized for localized delivery of pharmaceutically active agents to body tissue other than the eye, if desired.
  • Eye 52 has a cornea 54 , a lens 56 , a sclera 58 , a choroid 60 , a retina 62 , and an optic nerve 64 .
  • An anterior segment 66 of eye 52 generally includes the portions of eye 52 anterior of a line 67 .
  • a posterior segment 68 of eye 52 generally includes the portions of eye 52 posterior of line 67 .
  • Retina 62 is physically attached to choroid 60 in a circumferential manner proximate pars plana 70 .
  • Retina 62 has a macula 72 located slightly lateral to its optic disk.
  • macula 72 is comprised primarily of retinal cones and is the region of maximum visual acuity in retina 62 .
  • a Tenon's capsule or Tenon's membrane 74 is disposed on sclera 58 .
  • a conjunctiva 76 covers a short area of the globe of eye 52 posterior to limbus 77 (the bulbar conjunctiva) and folds up (the upper cul-de-sac) or down (the lower cul-de-sac) to cover the inner areas of upper eyelid 78 and lower eyelid 79 , respectively.
  • Conjunctiva 76 is disposed on top of Tenon's capsule 74 . As is shown in FIGS.
  • device 50 is preferably disposed directly on the outer surface of sclera 58 , below Tenon's capsule 74 for treatment of most posterior segment diseases or conditions.
  • device 50 is preferably disposed directly on the outer surface of sclera 58 , below Tenon's capsule 74 , with an inner core of device 50 proximate macula 72 .
  • FIGS. 5, 6A , and 6 B schematically illustrate drug delivery device 50 in greater detail.
  • Device 50 generally includes a body 80 having a scleral surface 82 and an orbital surface 84 .
  • Scleral surface 82 is preferably designed with a radius of curvature that facilitates direct contact with sclera 58 .
  • Orbital surface 84 is preferably designed with a radius of curvature that facilitates implantation under Tenon's capsule 74 .
  • Body 80 preferably has a curved, generally rectangular three-dimensional geometry with rounded sides 86 and 88 , proximal end 90 , and distal end 92 . As shown best in the side sectional view of FIG.
  • orbital surface 84 preferably has tapered surfaces 94 and 96 proximate proximal end 90 and distal end 92 , respectively, that facilitate sub-Tenon implantation of device 50 and enhance the comfort of the patient.
  • Body 80 may alternatively have a geometry similar to that of device 10 a shown in FIG. 2 .
  • body 80 may have any other geometry that has a curved scleral surface 82 for contact with sclera 58 .
  • body 80 may have a generally cylindrical, oval, square, or other polygonal three-dimensional geometry.
  • Body 80 includes a well or cavity 102 having an opening 104 to scleral surface 82 .
  • An inner core 106 is preferably disposed in well 102 .
  • Inner core 106 is preferably a tablet comprising one or more pharmaceutically active agents.
  • inner core 106 may comprise a conventional hydrogel having one or more pharmaceutically active agents disposed therein.
  • a retaining member 108 is preferably disposed proximate opening 104 . Retaining member 108 prevents inner core 106 from falling out of well 102 .
  • retaining member 108 is preferably a continuous rim or lip disposed circumferentially around opening 104 having a diameter slightly less than the diameter of tablet 106 .
  • retaining member 108 may comprise one or more members that extend from body 80 into opening 104 .
  • inner core 106 may alternatively comprise a suspension, solution, powder, or combination thereof containing one or more pharmaceutically active agents.
  • scleral surface 82 is formed without opening 104 , and the suspension, solution, powder, or combination thereof diffuses through the relatively thin portion of scleral surface 82 below inner core 26 .
  • device 50 may be formed without well 102 or inner core 106 , and the pharmaceutically active agent(s) in the form of a suspension, solution, powder, or combination thereof may be dispersed throughout body 80 of device 50 . In this embodiment, the pharmaceutically active agent diffuses through body 80 into the target tissue.
  • the geometry and dimensions of device 50 maximize communication between the pharmaceutically active agent of inner core 106 and the tissue underlying scleral surface 82 .
  • Scleral surface 82 preferably physically contacts the outer surface of sclera 58 .
  • inner core 106 may be formed so that surface 106 a physically contacts the outer surface of sclera 58 .
  • scleral surface 82 may be disposed proximate the outer surface of sclera 58 .
  • device 50 may be disposed in the periocular tissues just above the outer surface of sclera 58 or intra-lamellarly within sclera 58 .
  • Body 80 preferably comprises a biocompatible, non-bioerodable material.
  • Body 80 more preferably comprises a biocompatible, non-bioerodable polymeric composition.
  • Body 80 most preferably is made from a polymeric composition comprising silicone.
  • Body 80 is preferably impermeable to the pharmaceutically active agent of inner core 106 .
  • the diameter of well 102 may be slightly less than the diameter of inner core 106 . This frictional fit secures inner core 106 within well 102 .
  • body 80 may be formed without retaining member 108 , if desired.
  • Inner core 106 may comprise any ophthalmically acceptable pharmaceutically active agents suitable for localized delivery.
  • Exemplary pharmaceutically active agents include the pharmaceutically active agents listed hereinabove for inner core 26 of device 10 .
  • Inner core 106 may also comprise conventional non-active excipients to enhance the stability, solubility, penetrability, or other properties of the active agent.
  • inner core 106 is a tablet, it may further comprise conventional excipients necessary for tableting, such as fillers and lubricants. Such tablets may be produced using conventional tableting methods.
  • the pharmaceutically active agent is preferably distributed evenly throughout the tablet.
  • inner core 106 may comprise a special tablet that bioerodes at a controlled rate, releasing the pharmaceutically active agent. By way of example, such bioerosion may occur through hydrolosis or enzymatic cleavage.
  • inner core 106 is a hydrogel, the hydrogel may bioerode at a controlled rate, releasing the pharmaceutically active agent. Alternatively, the hydrogel may be non-bioerodable but allow diffusion of the pharmaceutically active agent.
  • Device 50 may be made by conventional polymer processing methods, including, but not limited to, injection molding, extrusion molding, transfer molding, and compression molding. Preferably, device 50 is formed using conventional injection molding techniques as described hereinabove for device 10 .
  • Device 50 is preferably surgically placed directly on the outer surface of sclera 58 below Tenon's capsule 74 using a simple surgical technique that is capable of being performed in an outpatient setting.
  • the surgeon first performs a peritomy in one of the quadrants of eye 52 .
  • the surgeon performs the peritomy in the infra-temporal quadrant, about 3 mm posterior to limbus 77 of eye 52 .
  • the surgeon performs a blunt dissection to separate Tenon's capsule 74 from sclera 58 , forming an antero-posterior tunnel.
  • the surgeon uses forceps to hold device 50 with scleral surface 82 facing sclera 58 and distal end 92 away from the surgeon.
  • the surgeon then introduces device 50 into the tunnel in a generally circular motion to position inner core 106 of device 50 generally above the desired portion of retina 62 .
  • the surgeon then closes the peritomy by suturing Tenon's capsule 74 and conjunctiva 76 to sclera 58 . After closing, the surgeon places a strip of antibiotic ointment on the surgical wound.
  • the surgeon may suture proximal end 90 of device 50 to sclera 58 to hold device 50 in the desired location before closure of the tunnel.
  • the surgeon utilizes the above-described technique to position inner core 106 of device 50 in one of two preferred locations in the infra-temporal quadrant of eye 52 .
  • One preferred location is directly on the outer surface of sclera 58 , below Tenon's capsule 74 , with inner core 106 positioned proximate to, but not directly above, macula 72 .
  • a surgeon may position inner core 106 of device 50 at this location by moving distal end 92 of device 50 below the inferior oblique muscle in a direction generally parallel to the lateral rectus muscle.
  • a second preferred location is directly on the outer surface of sclera 58 , below Tenon's capsule 74 , with inner core 106 positioned directly above macula 72 .
  • a surgeon may position inner core 106 of device 50 at this location by moving distal end 92 of device 50 toward macula 72 along a path generally between the lateral and inferior rectus muscles and below the inferior oblique muscle.
  • the pharmaceutically active agent of inner core 106 is preferably one of the angiostatic steroids disclosed in U.S. Pat. Nos. 5,679,666 and 5,770,592.
  • body 80 of device 50 including the geometry of scleral surface 82 , well 102 , opening 104 , and retaining member 108 , facilitate the unidirectional delivery of a pharmaceutically effective amount of the pharmaceutically active agent from inner core 106 through sclera 58 , choroid 60 , and into retina 62 .
  • the absence of a polymer layer or membrane between inner core 106 and sclera 58 greatly enhances and simplifies the delivery of an active agent to retina 62 .
  • device 50 can be used to deliver a pharmaceutically effective amount of a pharmaceutically active agent to retina 62 for many years, depending on the particular physicochemical properties of the pharmaceutically active agent employed.
  • Important physicochemical properties include hydrophobicity, solubility, dissolution rate, diffusion coefficient, and tissue affinity.
  • a device 50 was surgically implanted on the outer surface of the sclera, below the Tenon's capsule, generally along the inferior border of the lateral rectus muscle of the right eye of twenty (20) New Zealand White rabbits using a procedure similar to that described hereinabove for implantation of device 50 on sclera 58 of eye 52 .
  • Device 50 was constructed as shown in FIGS. 5 through 6 B, with the following dimensions.
  • Body 80 had a length 110 of about 15 mm, a width 112 of about 7.0 mm, and a maximum thickness 114 of about 1.8 mm.
  • Retaining member 108 had a thickness 116 of about 0.15 mm.
  • Scleral surface 82 had a radius of curvature of about 8.5 mm and an arc length of about 18 mm.
  • Inner core 106 was a cylindrical tablet with a diameter of about 5.0 mm and a thickness of about 1.5 mm. Opening 104 had a diameter of about 3.8 mm. Well 102 had a diameter of about 4.4 mm.
  • the pharmaceutically active agent used in tablet 106 was 4,9(11)-Pregnadien-17 ⁇ ,21-diol-3,20-dione, an angiostatic steroid sold by Steraloids, Inc. of Wilton, N.H., and which is more fully disclosed in U.S. Pat. Nos. 5,770,592 and 5,679,666.
  • the formulation of tablet 106 consisted of 99.75 weight percent 4,9(11)-Pregnadien-17 ⁇ ,21-diol-3,20-dione, and 0.25 weight percent magnesium stearate.
  • a 10 mm diameter circular zone of retinal tissue was harvested (the “target site”).
  • a 10 mm diameter circular zone of retinal tissue was also harvested from a second site located remote from the target site and on the other side of the optic nerve.
  • a 10 mm diameter circular zone of retinal tissue was harvested from a third site located between the second site and the target site.
  • FIG. 7 shows the mean concentration of 4,9(11)-Pregnadien-17 ⁇ ,21-diol-3,20-dione in the retina and the choroid at the target site as a function of time.
  • the “error bars” surrounding each data point represent standard deviation.
  • device 50 delivered a pharmaceutically effective and generally constant amount of 4,9(11)-Pregnadien-17 ⁇ ,21-diol-3,20-dione to the retina and the choroid at the target site for a time period of up to twelve weeks.
  • the levels of 4,9(11)-Pregnadien-17 ⁇ ,21-diol-3,20-dione in the retina and the choroid at the second and third sites were at or near zero. Therefore, device 50 also delivered a localized dose of angiostatic steroid to the retina and the choroid at the target site.
  • the present invention provides improved devices and methods for safe, effective, rate-controlled, localized delivery of a variety of pharmaceutically active agents to any body tissue.
  • the surgical procedure for implanting such devices is safe, simple, quick, and capable of being performed in an outpatient setting.
  • Such devices are easy and economical to manufacture.
  • such devices are useful in clinical studies to deliver various agents that create a specific physical condition in a patient or animal subject.
  • such devices are especially useful for localized delivery of pharmaceutically active agents to the posterior segment of the eye to combat ARMD, CNV, retinopathies, retinitis, uveitis, macular edema, and glaucoma.

Abstract

Drug delivery devices, and methods of delivering pharmaceutically active agents to a target tissue within a body using such devices, are disclosed. One drug delivery device includes a body having an internal surface for placement proximate a target tissue and a well having an opening to the internal surface. An inner core comprising a pharmaceutically active agent is disposed in the well.

Description

  • This application is a continuation of U.S. application Ser. No. 10/186,960, filed Jul. 1, 2002, which is a continuation of U.S. application Ser. No. 09/660,000, filed Sep. 12, 2000, now U.S. Pat. No. 6,413,540, which claims priority from U.S. Provisional Application No. 60/160,673, filed Oct. 21, 1999.
  • FIELD OF THE INVENTION
  • The present invention generally pertains to biocompatible implants for localized delivery of pharmaceutically active agents to body tissue. More particularly, but not by way of limitation, the present invention pertains to biocompatible implants for localized delivery of pharmaceutically active agents to the posterior segment of the eye.
  • DESCRIPTION OF THE RELATED ART
  • Several diseases and conditions of the posterior segment of the eye threaten vision. Age related macular degeneration (ARMD), choroidal neovascularization (CNV), retinopathies (i.e. diabetic retinopathy, vitreoretinopathy), retinitis (i.e. cytomegalovirus (CMV) retinitis), uveitis, macular edema, and glaucoma are several examples.
  • Age related macular degeneration (ARMD) is the leading cause of blindness in the elderly. ARMD attacks the center of vision and blurs it, making reading, driving, and other detailed tasks difficult or impossible. About 200,000 new cases of ARMD occur each year in the United States alone. Current estimates reveal that approximately forty percent of the population over age 75, and approximately twenty percent of the population over age 60, suffer from some degree of macular degeneration. “Wet” ARMD is the type of ARMD that most often causes blindness. In wet ARMD, newly formed choroidal blood vessels (choroidal neovascularization (CNV)) leak fluid and cause progressive damage to the retina.
  • In the particular case of CNV in ARMD, two main methods of treatment are currently being developed, (a) photocoagulation and (b) the use of angiogenesis inhibitors. However, photocoagulation can be harmful to the retina and is impractical when the CNV is near the fovea. Furthermore, photocoagulation often results in recurrent CNV over time. Oral or parenteral (non-ocular) administration of anti-angiogenic compounds is also being tested as a systemic treatment for ARMD. However, due to drug-specific metabolic restrictions, systemic administration usually provides sub-therapeutic drug levels to the eye. Therefore, to achieve effective intraocular drug concentrations, either an unacceptably high dose or repetitive conventional doses are required. Periocular injections of these compounds often result in the drug being quickly washed out and depleted from the eye, via periocular vasculature and soft tissue, into the general circulation. Repetitive intraocular injections may result in severe, often blinding, complications such as retinal detachment and endophthalmitis.
  • In order to prevent complications related to the above-described treatments and to provide better ocular treatment, researchers have suggested various implants aimed at localized delivery of anti-angiogenic compounds to the eye. U.S. Pat. No. 5,824,072 to Wong discloses a non-biodegradable polymeric implant with a pharmaceutically active agent disposed therein. The pharmaceutically active agent diffuses through the polymer body of the implant into the target tissue. The pharmaceutically active agent may include drugs for the treatment of macular degeneration and diabetic retinopathy. The implant is placed substantially within the tear fluid upon the outer surface of the eye over an avascular region, and may be anchored in the conjunctiva or sclera; episclerally or intrasclerally over an avascular region; substantially within the suprachoroidial space over an avascular region such as the pars plana or a surgically induced avascular region; or in direct communication with the vitreous.
  • U.S. Pat. No. 5,476,511 to Gwon et al. discloses a polymer implant for placement under the conjunctiva of the eye. The implant may be used to deliver neovascular inhibitors for the treatment of ARMD and drugs for the treatment of retinopathies, retinitis, and CMV retinitis. The pharmaceutically active agent diffuses through the polymer body of the implant.
  • U.S. Pat. No. 5,773,019 to Ashton et al. discloses a non-bioerodable polymer implant for delivery of certain drugs including angiostatic steroids and drugs such as cyclosporine for the treatment of uveitis. Once again, the pharmaceutically active agent diffuses through the polymer body of the implant.
  • All of the above-described implants require careful design and manufacture to permit controlled diffusion of the pharmaceutically active agent through a polymer body (matrix devices) or polymer membrane (reservoir devices) to the desired site of therapy. Drug release from these devices depends on the porosity and diffusion characteristics of the matrix or membrane, respectively. These parameters must be tailored for each drug moiety to be used with these devices. Consequently, these requirements generally increase the complexity and cost of such implants.
  • U.S. Pat. No. 5,824,073 to Peyman discloses an indentor for positioning in the eye. The indentor has a raised portion that is used to indent or apply pressure to the sclera over the macular area of the eye. This patent discloses that such pressure decreases choroidal congestion and blood flow through the subretinal neovascular membrane, which, in turn, decreases bleeding and subretinal fluid accumulation.
  • Therefore, a need exists in the biocompatible implant field for a surgically implantable drug delivery device capable of safe, effective, rate-controlled, localized delivery of a wide variety of pharmaceutically active agents to any body tissue. The surgical procedure for implanting such a device should be safe, simple, quick, and capable of being performed in an outpatient setting. Ideally, such a device should be easy and economical to manufacture. Furthermore, because of its versatility and capability to deliver a wide variety of pharmaceutically active agents, such an implant should be capable of use in clinical studies to deliver various agents that create a specific physical condition in a patient or animal subject. In the particular field of ophthalmic drug delivery, such an implantable drug delivery device is especially needed for localized delivery of pharmaceutically active agents to the posterior segment of the eye to combat ARMD, CNV, retinopathies, retinitis, uveitis, macular edema, and glaucoma.
  • SUMMARY OF THE INVENTION
  • One aspect of the present invention comprises a drug delivery device including a body having an internal surface for placement proximate a target tissue and a well having an opening to the internal surface. An inner core comprising a pharmaceutically active agent is disposed in the well.
  • In another aspect, the present invention comprises a method of delivering a pharmaceutically active agent to a target tissue within a body. A drug delivery device is provided. The drug delivery device includes a body having an internal surface and a well having an opening to the internal surface, and an inner core disposed in the well comprising a pharmaceutically active agent. The device is disposed within the body so that the pharmaceutically active agent is in communication with the target tissue through the opening.
  • In a further aspect, the present invention comprises an ophthalmic drug delivery device including a body having a scleral surface for placement proximate a sclera and a well or cavity having an opening to the scleral surface. An inner core comprising a pharmaceutically active agent is disposed in the well.
  • In a further aspect, the present invention comprises a method of delivering a pharmaceutically active agent to an eye having a sclera. A drug delivery device is provided. The drug delivery device includes a body having a scleral surface and a well having an opening to the scleral surface, and an inner core disposed in the well comprising a pharmaceutically active agent. The device is disposed within the eye so that the pharmaceutically active agent is in communication with the sclera through the opening.
  • In a further aspect, the present invention comprises a method of delivering a pharmaceutically active agent to an eye having a sclera, a Tenon's capsule, and a macula. A drug delivery device comprising a body having a pharmaceutically active agent disposed therein is provided. The device is disposed on an outer surface of the sclera, below the Tenon's capsule, and proximate the macula.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • For a more complete understanding of the present invention, and for further objects and advantages thereof, reference is made to the following description taken in conjunction with the accompanying drawings in which:
  • FIG. 1 is a side sectional view of a drug delivery device according to a preferred embodiment of the present invention;
  • FIG. 2 is a side sectional view of a second drug delivery device according to a preferred embodiment of the present invention;
  • FIG. 3 is a side sectional view schematically illustrating the human eye;
  • FIG. 4 is detailed cross-sectional view of the eye of FIG. 3 along line 4-4;
  • FIG. 5 is a perspective view of an ophthalmic drug delivery device according to a preferred embodiment of the present invention;
  • FIG. 6A is a side sectional view of the ophthalmic drug delivery device of FIG. 5;
  • FIG. 6B is an enlarged cross-sectional view of the ophthalmic drug delivery device of FIG. 6A taken along line 6B-6B; and
  • FIG. 7 is a graphical illustration of the results of a pharmacokinetic study with New Zealand White rabbits implanted with the ophthalmic drug delivery device of FIGS. 5 through 6B showing the mean concentration of a pharmaceutically active agent at a target site in the retina and choroid of the rabbits as a function of time.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • The preferred embodiments of the present invention and their advantages are best understood by referring to FIGS. 1 through 7 of the drawings, like numerals being used for like and corresponding parts of the various drawings.
  • FIG. 1 schematically illustrates a drug delivery device 10 according to a preferred embodiment of the present invention. Device 10 may be used in any case where localized delivery of a pharmaceutically active agent to body tissue is required. By way of example, device 10 may be used to treat a medical disorder of the eye, ear, nose, throat, skin, subcutaneous tissue, or bone. Device 10 may be used in humans or animals.
  • Device 10 generally includes a body 12 having an internal surface 14 and an external surface 16. As shown in FIG. 1, body 12 preferably has a generally rectangular three-dimensional geometry with a proximal end 18 and a distal end 20. Body 12 may have any other geometry that has an internal surface 14 for placement proximate a target tissue in the body of a patient. By way of example, body 12 may have a cylindrical, an oval, a square, or other polygonal three-dimensional geometry.
  • Body 12 includes a well or cavity 22 having an opening 24 to internal surface 14. An inner core 26 is preferably disposed in well 22. Inner core 26 is preferably a tablet comprising one or more pharmaceutically active agents. Alternatively, inner core 26 may comprise a conventional hydrogel having one or more pharmaceutically active agents disposed therein. A retaining member 28 is preferably disposed proximate opening 24. Retaining member 28 prevents inner core 26 from falling out of well 22. When inner core 26 is a cylindrical tablet, retaining member 28 is preferably a continuous rim or lip disposed circumferentially around opening 24 having a diameter slightly less than the diameter of tablet 26. Alternatively, retaining member 26 may comprise one or more members that extend from body 12 into opening 24. Although not shown in FIG. 1, inner core 26 may alternatively comprise a suspension, solution, powder, or combination thereof containing one or more pharmaceutically active agents. In this embodiment, internal surface 14 is formed without opening 24, and the suspension, solution, powder, or combination thereof diffuses through the relatively thin portion of internal surface 14 below inner core 26. Still further in the alternative, device 10 may be formed without well 22 or inner core 26, and the pharmaceutically active agent(s) in the form of a suspension, solution, powder, or combination thereof may be dispersed throughout body 12 of device 10. In this embodiment, the pharmaceutically active agent diffuses through body 12 into the target tissue.
  • The geometry of device 10 maximizes communication between the pharmaceutically active agent of inner core 26 and the tissue underlying internal surface 14. Internal surface 14 preferably physically contacts the target tissue. By way of example, if the target tissue has a generally flat surface, device 10 would be appropriate for the delivery of a pharmaceutically active agent. As another example, if the target tissue has a generally convex surface, a device 10 a shown in FIG. 2 having a generally concave internal surface 14 a designed to mate with such a target surface may be utilized. Corners 30 of proximal end 18 a, and corners 32 of distal end 20 a, may be slanted and/or rounded off to facilitate surgical placement of device 10 a and to maximize comfort to the patient. Retaining member 28 is preferably designed with a minimum thickness necessary to retain inner core 26 so as to dispose a surface 26 a of inner core 26 in close proximity to the target tissue. Although not shown in FIG. 1 or 2, inner core 26 may be formed so that surface 26 a physically contacts the target tissue.
  • Alternatively, device 10 or 10 a may be disposed in the body of a patient so that internal surface 14 or 14 a is disposed proximate the target tissue. In this case, internal surface 14 or 14 a physically contacts intermediate tissue disposed between it and the target tissue. The pharmaceutically active agent of inner core 26 communicates with the target tissue through opening 24 and this intermediate tissue.
  • Referring again to FIG. 1, body 12 preferably comprises a biocompatible, non-bioerodable material. Body 12 more preferably comprises a biocompatible, non-bioerodable polymeric composition. Said polymeric composition may be a homopolymer, a copolymer, straight, branched, cross-linked, or a blend. Examples of polymers suitable for use in said polymeric composition include silicone, polyvinyl alcohol, ethylene vinyl acetate, polylactic acid, nylon, polypropylene, polycarbonate, cellulose, cellulose acetate, polyglycolic acid, polylactic-glycolic acid, cellulose esters, polyethersulfone, acrylics, their derivatives, and combinations thereof. Examples of suitable soft acrylics are more fully disclosed in U.S. Pat. No. 5,403,901, which is incorporated herein in its entirety by reference. Said polymeric composition most preferably comprises silicone. Of course, said polymeric composition may also comprise other conventional materials that affect its physical properties, including, but not limited to, porosity, tortuosity, permeability, rigidity, hardness, and smoothness. Exemplary materials affecting certain ones of these physical properties include conventional plasticizers, fillers, and lubricants. Said polymeric composition may comprise other conventional materials that affect its chemical properties, including, but not limited to, toxicity, hydrophobicity, and body 12inner core 26 interaction. Body 12 is preferably impermeable to the pharmaceutically active agent of inner core 26. When body 12 is made from a generally elastic polymeric composition, the diameter of well 22 may be slightly less than the diameter of inner core 26. This frictional fit secures inner core 26 within well 22. In this embodiment, body 12 may be formed without retaining member 28, if desired.
  • Inner core 26 may comprise any pharmaceutically active agents suitable for localized delivery to a target tissue. Examples of pharmaceutically active agents suitable for inner core 26 are anti-infectives, including, without limitation, antibiotics, antivirals, and antifungals; antiallergenic agents and mast cell stabilizers; steroidal and non-steroidal anti-inflammatory agents; combinations of anti-infective and anti-inflammatory agents; decongestants; anti-glaucoma agents, including, without limitation, adrenergics, β-adrenergic blocking agents, α-adrenergic agonists, parasypathomimetic agents, cholinesterase inhibitors, carbonic anhydrase inhibitors, and prostaglandins; combinations of anti-glaucoma agents; antioxidants; nutritional supplements; drugs for the treatment of cystoid macular edema including, without limitation, non-steroidal anti-inflammatory agents; drugs for the treatment of ARMD, including, without limitation, angiogenesis inhibitors and nutritional supplements; drugs for the treatment of herpetic infections and CMV ocular infections; drugs for the treatment of proliferative vitreoretinopathy including, without limitation, antimetabolites and fibrinolytics; wound modulating agents, including, without limitation, growth factors; antimetabolites; neuroprotective drugs, including, without limitation, eliprodil; and angiostatic steroids for the treatment of diseases or conditions of the posterior segment of the eye, including, without limitation, ARMD, CNV, retinopathies, retinitis, uveitis, macular edema, and glaucoma. Such angiostatic steroids are more fully disclosed in U.S. Pat. Nos. 5,679,666 and 5,770,592, which are incorporated herein in their entirety by reference. Preferred ones of such angiostatic steroids include 4,9(11)-Pregnadien-17α,21-diol-3,20-dione and 4,9(11)-Pregnadien-17α,21-diol-3,20-dione-21-acetate. Inner core 26 may also comprise conventional non-active excipients to enhance the stability, solubility, penetrability, or other properties of the active agent or the drug core.
  • If inner core 26 is a tablet, it may further comprise conventional excipients necessary for tableting, such as fillers and lubricants. Such tablets may be produced using conventional tableting methods. The pharmaceutically active agent is preferably distributed evenly throughout the tablet. In addition to conventional tablets, inner core 26 may comprise a special tablet that bioerodes at a controlled rate, releasing the pharmaceutically active agent. By way of example, such bioerosion may occur through hydrolosis or enzymatic cleavage. If inner core 26 is a hydrogel, the hydrogel may bioerode at a controlled rate, releasing the pharmaceutically active agent. Alternatively, the hydrogel may be non-bioerodable but allow diffusion of the pharmaceutically active agent.
  • Device 10 may be made by conventional polymer processing methods, including, but not limited to, injection molding, extrusion molding, transfer molding, and compression molding. Preferably, device 10 is formed using conventional injection molding techniques. Inner core 26 is preferably disposed in well 22 after the formation of body 12 of device 10. Retaining member 28 is preferably resilient enough to allow inner core 26 to be inserted through opening 24 and then to return to its position as shown in FIG. 1.
  • Device 10 is preferably surgically placed proximate a target tissue. The surgeon first makes an incision proximate the target tissue. Next, the surgeon performs a blunt dissection to a level at or near the target tissue. Once the target tissue is located, the surgeon uses forceps to hold device 10 with internal surface 14 facing the target tissue and distal end 20 away from the surgeon. The surgeon then introduces device 10 into the dissection tunnel, and positions device 10 with internal surface 14 facing the target tissue. Once in place, the surgeon may or may not use sutures to fix device 10 to the underlying tissue, depending on the specific tissue. After placement, the surgeon sutures the opening and places a strip of antibiotic ointment on the surgical wound.
  • The physical shape of body 12, including the geometry of internal surface 14, well 22, opening 24, and retaining member 28, facilitate the unidirectional delivery of a pharmaceutically effective amount of the pharmaceutically active agent from inner core 26 to the target tissue. In particular, the absence of a polymer layer or membrane between inner core 26 and the underlying tissue greatly enhances and simplifies the delivery of an active agent to the target tissue.
  • Device 10 can be used to deliver a pharmaceutically effective amount of a pharmaceutically active agent to target tissue for many years, depending on the particular physicochemical properties of the pharmaceutically active agent employed. Important physicochemical properties include hydrophobicity, solubility, dissolution rate, diffusion coefficient, and tissue affinity. After inner core 26 no longer contains active agent, a surgeon may easily remove device 10. In addition, the “preformed” tunnel facilitates the replacement of an old device 10 with a new device 10.
  • FIGS. 3 through 6B schematically illustrate an ophthalmic drug delivery device 50 according to a preferred embodiment of the present invention. Device 50 may be used in any case where localized delivery of a pharmaceutically active agent to the eye is required. Device 50 is particularly useful for localized delivery of active agents to the posterior segment of the eye. A preferred use for device 50 is the delivery of pharmaceutically active agents to the retina proximate the macula for treating ARMD, choroidial neovascularization (CNV), retinopathies, retinitis, uveitis, macular edema, and glaucoma. Of course, device 50 may also be utilized for localized delivery of pharmaceutically active agents to body tissue other than the eye, if desired.
  • Referring first to FIG. 3, a human eye 52 is schematically illustrated. Eye 52 has a cornea 54, a lens 56, a sclera 58, a choroid 60, a retina 62, and an optic nerve 64. An anterior segment 66 of eye 52 generally includes the portions of eye 52 anterior of a line 67. A posterior segment 68 of eye 52 generally includes the portions of eye 52 posterior of line 67. Retina 62 is physically attached to choroid 60 in a circumferential manner proximate pars plana 70. Retina 62 has a macula 72 located slightly lateral to its optic disk. As is well known in the ophthahnic art, macula 72 is comprised primarily of retinal cones and is the region of maximum visual acuity in retina 62. A Tenon's capsule or Tenon's membrane 74 is disposed on sclera 58. A conjunctiva 76 covers a short area of the globe of eye 52 posterior to limbus 77 (the bulbar conjunctiva) and folds up (the upper cul-de-sac) or down (the lower cul-de-sac) to cover the inner areas of upper eyelid 78 and lower eyelid 79, respectively. Conjunctiva 76 is disposed on top of Tenon's capsule 74. As is shown in FIGS. 3 and 4, and as is described in greater detail hereinbelow, device 50 is preferably disposed directly on the outer surface of sclera 58, below Tenon's capsule 74 for treatment of most posterior segment diseases or conditions. In addition, for treatment of ARMD in humans, device 50 is preferably disposed directly on the outer surface of sclera 58, below Tenon's capsule 74, with an inner core of device 50 proximate macula 72.
  • FIGS. 5, 6A, and 6B schematically illustrate drug delivery device 50 in greater detail. Device 50 generally includes a body 80 having a scleral surface 82 and an orbital surface 84. Scleral surface 82 is preferably designed with a radius of curvature that facilitates direct contact with sclera 58. Orbital surface 84 is preferably designed with a radius of curvature that facilitates implantation under Tenon's capsule 74. Body 80 preferably has a curved, generally rectangular three-dimensional geometry with rounded sides 86 and 88, proximal end 90, and distal end 92. As shown best in the side sectional view of FIG. 6A, orbital surface 84 preferably has tapered surfaces 94 and 96 proximate proximal end 90 and distal end 92, respectively, that facilitate sub-Tenon implantation of device 50 and enhance the comfort of the patient. Body 80 may alternatively have a geometry similar to that of device 10 a shown in FIG. 2. In addition, body 80 may have any other geometry that has a curved scleral surface 82 for contact with sclera 58. By way of example, body 80 may have a generally cylindrical, oval, square, or other polygonal three-dimensional geometry.
  • Body 80 includes a well or cavity 102 having an opening 104 to scleral surface 82. An inner core 106 is preferably disposed in well 102. Inner core 106 is preferably a tablet comprising one or more pharmaceutically active agents. Alternatively, inner core 106 may comprise a conventional hydrogel having one or more pharmaceutically active agents disposed therein. A retaining member 108 is preferably disposed proximate opening 104. Retaining member 108 prevents inner core 106 from falling out of well 102. When inner core 106 is a cylindrical tablet, retaining member 108 is preferably a continuous rim or lip disposed circumferentially around opening 104 having a diameter slightly less than the diameter of tablet 106. Alternatively, retaining member 108 may comprise one or more members that extend from body 80 into opening 104. Although not shown in FIG. 6A, inner core 106 may alternatively comprise a suspension, solution, powder, or combination thereof containing one or more pharmaceutically active agents. In this embodiment, scleral surface 82 is formed without opening 104, and the suspension, solution, powder, or combination thereof diffuses through the relatively thin portion of scleral surface 82 below inner core 26. Still further in the alternative, device 50 may be formed without well 102 or inner core 106, and the pharmaceutically active agent(s) in the form of a suspension, solution, powder, or combination thereof may be dispersed throughout body 80 of device 50. In this embodiment, the pharmaceutically active agent diffuses through body 80 into the target tissue.
  • The geometry and dimensions of device 50 maximize communication between the pharmaceutically active agent of inner core 106 and the tissue underlying scleral surface 82. Scleral surface 82 preferably physically contacts the outer surface of sclera 58. Although not shown in FIG. 6A or 6B, inner core 106 may be formed so that surface 106 a physically contacts the outer surface of sclera 58. Alternatively, scleral surface 82 may be disposed proximate the outer surface of sclera 58. By way of example, device 50 may be disposed in the periocular tissues just above the outer surface of sclera 58 or intra-lamellarly within sclera 58.
  • Body 80 preferably comprises a biocompatible, non-bioerodable material. Body 80 more preferably comprises a biocompatible, non-bioerodable polymeric composition. The polymeric composition comprising body 80, and the polymers suitable for use in the polymeric compositions of body 80, may be any of the compositions and polymers described hereinabove for body 12 of device 10. Body 80 most preferably is made from a polymeric composition comprising silicone. Body 80 is preferably impermeable to the pharmaceutically active agent of inner core 106. When body 80 is made from a generally elastic polymeric composition, the diameter of well 102 may be slightly less than the diameter of inner core 106. This frictional fit secures inner core 106 within well 102. In this embodiment, body 80 may be formed without retaining member 108, if desired.
  • Inner core 106 may comprise any ophthalmically acceptable pharmaceutically active agents suitable for localized delivery. Exemplary pharmaceutically active agents include the pharmaceutically active agents listed hereinabove for inner core 26 of device 10. Inner core 106 may also comprise conventional non-active excipients to enhance the stability, solubility, penetrability, or other properties of the active agent.
  • If inner core 106 is a tablet, it may further comprise conventional excipients necessary for tableting, such as fillers and lubricants. Such tablets may be produced using conventional tableting methods. The pharmaceutically active agent is preferably distributed evenly throughout the tablet. In addition to conventional tablets, inner core 106 may comprise a special tablet that bioerodes at a controlled rate, releasing the pharmaceutically active agent. By way of example, such bioerosion may occur through hydrolosis or enzymatic cleavage. If inner core 106 is a hydrogel, the hydrogel may bioerode at a controlled rate, releasing the pharmaceutically active agent. Alternatively, the hydrogel may be non-bioerodable but allow diffusion of the pharmaceutically active agent.
  • Device 50 may be made by conventional polymer processing methods, including, but not limited to, injection molding, extrusion molding, transfer molding, and compression molding. Preferably, device 50 is formed using conventional injection molding techniques as described hereinabove for device 10.
  • Device 50 is preferably surgically placed directly on the outer surface of sclera 58 below Tenon's capsule 74 using a simple surgical technique that is capable of being performed in an outpatient setting. The surgeon first performs a peritomy in one of the quadrants of eye 52. Preferably, the surgeon performs the peritomy in the infra-temporal quadrant, about 3 mm posterior to limbus 77 of eye 52. Once this incision is made, the surgeon performs a blunt dissection to separate Tenon's capsule 74 from sclera 58, forming an antero-posterior tunnel. Once the tunnel is formed, the surgeon uses forceps to hold device 50 with scleral surface 82 facing sclera 58 and distal end 92 away from the surgeon. The surgeon then introduces device 50 into the tunnel in a generally circular motion to position inner core 106 of device 50 generally above the desired portion of retina 62. The surgeon then closes the peritomy by suturing Tenon's capsule 74 and conjunctiva 76 to sclera 58. After closing, the surgeon places a strip of antibiotic ointment on the surgical wound. Alternatively, the surgeon may suture proximal end 90 of device 50 to sclera 58 to hold device 50 in the desired location before closure of the tunnel.
  • In the case of ARMD in the human eye, the surgeon utilizes the above-described technique to position inner core 106 of device 50 in one of two preferred locations in the infra-temporal quadrant of eye 52. One preferred location is directly on the outer surface of sclera 58, below Tenon's capsule 74, with inner core 106 positioned proximate to, but not directly above, macula 72. A surgeon may position inner core 106 of device 50 at this location by moving distal end 92 of device 50 below the inferior oblique muscle in a direction generally parallel to the lateral rectus muscle. A second preferred location is directly on the outer surface of sclera 58, below Tenon's capsule 74, with inner core 106 positioned directly above macula 72. A surgeon may position inner core 106 of device 50 at this location by moving distal end 92 of device 50 toward macula 72 along a path generally between the lateral and inferior rectus muscles and below the inferior oblique muscle. For ARMD, the pharmaceutically active agent of inner core 106 is preferably one of the angiostatic steroids disclosed in U.S. Pat. Nos. 5,679,666 and 5,770,592.
  • The physical shape of body 80 of device 50, including the geometry of scleral surface 82, well 102, opening 104, and retaining member 108, facilitate the unidirectional delivery of a pharmaceutically effective amount of the pharmaceutically active agent from inner core 106 through sclera 58, choroid 60, and into retina 62. In particular, the absence of a polymer layer or membrane between inner core 106 and sclera 58 greatly enhances and simplifies the delivery of an active agent to retina 62.
  • It is believed that device 50 can be used to deliver a pharmaceutically effective amount of a pharmaceutically active agent to retina 62 for many years, depending on the particular physicochemical properties of the pharmaceutically active agent employed. Important physicochemical properties include hydrophobicity, solubility, dissolution rate, diffusion coefficient, and tissue affinity. After inner core 106 no longer contains active agent, a surgeon may easily remove device 50. In addition, the “pre-formed” tunnel facilitates the replacement of an old device 50 with a new device 50.
  • The following example illustrates effective drug delivery to a rabbit retina using a preferred embodiment and surgical technique of the present invention, but are in no way limiting.
  • EXAMPLE
  • A device 50 was surgically implanted on the outer surface of the sclera, below the Tenon's capsule, generally along the inferior border of the lateral rectus muscle of the right eye of twenty (20) New Zealand White rabbits using a procedure similar to that described hereinabove for implantation of device 50 on sclera 58 of eye 52. Device 50 was constructed as shown in FIGS. 5 through 6B, with the following dimensions. Body 80 had a length 110 of about 15 mm, a width 112 of about 7.0 mm, and a maximum thickness 114 of about 1.8 mm. Retaining member 108 had a thickness 116 of about 0.15 mm. Scleral surface 82 had a radius of curvature of about 8.5 mm and an arc length of about 18 mm. Inner core 106 was a cylindrical tablet with a diameter of about 5.0 mm and a thickness of about 1.5 mm. Opening 104 had a diameter of about 3.8 mm. Well 102 had a diameter of about 4.4 mm. The pharmaceutically active agent used in tablet 106 was 4,9(11)-Pregnadien-17α,21-diol-3,20-dione, an angiostatic steroid sold by Steraloids, Inc. of Wilton, N.H., and which is more fully disclosed in U.S. Pat. Nos. 5,770,592 and 5,679,666. The formulation of tablet 106 consisted of 99.75 weight percent 4,9(11)-Pregnadien-17α,21-diol-3,20-dione, and 0.25 weight percent magnesium stearate.
  • At one week after implantation, 4 rabbits were euthanized and their right eyes were enucleated. The device 50 was removed from the eyes, and the location of tablet 106 was marked on their sclerae. Following the removal of the anterior segment and the vitreous of each eye and inversion of the thus formed eye-cup, a 10 mm diameter circular zone of retinal tissue, concentric with and below the location of tablet 106 on the sclera, was harvested (the “target site”). A 10 mm diameter circular zone of retinal tissue was also harvested from a second site located remote from the target site and on the other side of the optic nerve. In addition, a 10 mm diameter circular zone of retinal tissue was harvested from a third site located between the second site and the target site. Similar 10 mm diameter circular zones of choroidal tissue were also harvested at the target site, second site, and third site. All these tissues were separately homogenized, and the concentration of angiostatic steroid in each of these tissues was determined via an ocular pharmacokinetic study using high performance liquid chromatography and mass spectrometry analysis (LC-MS/MS). This procedure was repeated at 3, 6, 9, and 12 weeks after implantation.
  • FIG. 7 shows the mean concentration of 4,9(11)-Pregnadien-17α,21-diol-3,20-dione in the retina and the choroid at the target site as a function of time. The “error bars” surrounding each data point represent standard deviation. As shown in FIG. 7, device 50 delivered a pharmaceutically effective and generally constant amount of 4,9(11)-Pregnadien-17α,21-diol-3,20-dione to the retina and the choroid at the target site for a time period of up to twelve weeks. In contrast, the levels of 4,9(11)-Pregnadien-17α,21-diol-3,20-dione in the retina and the choroid at the second and third sites were at or near zero. Therefore, device 50 also delivered a localized dose of angiostatic steroid to the retina and the choroid at the target site.
  • From the above, it may be appreciated that the present invention provides improved devices and methods for safe, effective, rate-controlled, localized delivery of a variety of pharmaceutically active agents to any body tissue. The surgical procedure for implanting such devices is safe, simple, quick, and capable of being performed in an outpatient setting. Such devices are easy and economical to manufacture. Furthermore, because of their capability to deliver a wide variety of pharmaceutically active agents, such devices are useful in clinical studies to deliver various agents that create a specific physical condition in a patient or animal subject. In the particular field of ophthalmic drug delivery, such devices are especially useful for localized delivery of pharmaceutically active agents to the posterior segment of the eye to combat ARMD, CNV, retinopathies, retinitis, uveitis, macular edema, and glaucoma.
  • It is believed that the operation and construction of the present invention will be apparent from the foregoing description. While the apparatus and methods shown or described above have been characterized as being preferred, various changes and modifications may be made therein without departing from the spirit and scope of the invention as defined in the following claims.

Claims (13)

1. An ophthalmic drug delivery device, comprising:
a body having:
a scleral surface having a radius of curvature that facilitates contact with a sclera of a human eye;
a well having an opening to said scleral surface; and
a geometry that facilitates disposing said device on an outer surface of said sclera, below a Tenon's capsule of said eye, and in a posterior segment of said eye; and
an inner core disposed in said well and comprising a pharmaceutically active agent.
2. The ophthalmic drug delivery device of claim 1, wherein said body has a geometry that facilitates disposing said device on said outer surface of said sclera, below said Tenon's capsule, and in said posterior segment so that said inner core is disposed proximate a macula of said eye.
3. The ophthalmic drug delivery device of claim 2, wherein said body has a geometry that facilitates disposing said device on said outer surface of said sclera, below said Tenon's capsule, and in said posterior segment so that said inner core is disposed generally above said macula.
4. The ophthalmic drug delivery device of claim 1, wherein said inner core is a tablet.
5. The ophthalmic drug delivery device of claim 4, wherein at least a portion of said body is made from a generally elastic material so that said generally elastic material, a geometry of said well, and a geometry of said tablet frictionally secure said tablet within said well.
6. The ophthalmic drug delivery device of claim 4, wherein said tablet is formulated to bioerode and release said pharmaceutically active agent at a controlled rate.
7. The ophthalmic drug delivery device of claim 1, wherein said inner core is a hydrogel.
8. The ophthalmic drug delivery device of claim 7, wherein said hydrogel is formulated to bioerode and release said pharmaceutically active agent at a controlled rate.
9. The ophthalmic drug delivery device of claim 7, wherein said pharmaceutically active agent diffuses through said hydrogel at a controlled rate.
10. The ophthalmic drug delivery device of claim 1, further comprising a retaining member extending from said body proximate said opening, and wherein said retaining member helps to retain said inner core in said well.
11. The ophthalmic drug delivery device of claim 10, wherein said retaining member comprises a rim at least partially disposed around said opening.
12. The ophthalmic drug delivery device of any one of claims 1-11, wherein said pharmaceutically active agent comprises a compound selected from the group consisting of 4,9(11)-Pregnadien-17α,21-diol-3,20-dione and 4,9(11)-Pregnadien-17α,21-diol-3,20-dione-21-acetate.
13. The ophthalmic drug delivery device of any one of claims 1-11, wherein said pharmaceutically active agent comprises eliprodil.
US10/957,910 1999-10-21 2004-10-04 Drug delivery device Abandoned US20050112175A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/957,910 US20050112175A1 (en) 1999-10-21 2004-10-04 Drug delivery device
US11/567,892 US7943162B2 (en) 1999-10-21 2006-12-07 Drug delivery device

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16067399P 1999-10-21 1999-10-21
US9660000A 2000-09-12 2000-09-12
US10/186,960 US6808719B2 (en) 1999-10-21 2002-07-01 Drug delivery device
US10/957,910 US20050112175A1 (en) 1999-10-21 2004-10-04 Drug delivery device

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/186,960 Continuation US6808719B2 (en) 1999-10-21 2002-07-01 Drug delivery device

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/567,892 Continuation-In-Part US7943162B2 (en) 1999-10-21 2006-12-07 Drug delivery device

Publications (1)

Publication Number Publication Date
US20050112175A1 true US20050112175A1 (en) 2005-05-26

Family

ID=22577913

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/660,000 Expired - Lifetime US6413540B1 (en) 1999-10-21 2000-09-12 Drug delivery device
US10/186,960 Expired - Lifetime US6808719B2 (en) 1999-10-21 2002-07-01 Drug delivery device
US10/957,910 Abandoned US20050112175A1 (en) 1999-10-21 2004-10-04 Drug delivery device

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/660,000 Expired - Lifetime US6413540B1 (en) 1999-10-21 2000-09-12 Drug delivery device
US10/186,960 Expired - Lifetime US6808719B2 (en) 1999-10-21 2002-07-01 Drug delivery device

Country Status (22)

Country Link
US (3) US6413540B1 (en)
EP (2) EP1221917B1 (en)
JP (1) JP4837861B2 (en)
KR (1) KR100732262B1 (en)
CN (1) CN1292721C (en)
AR (3) AR026165A1 (en)
AT (2) ATE283013T1 (en)
AU (2) AU768400B2 (en)
BR (1) BR0014929B1 (en)
CA (1) CA2383499C (en)
CY (1) CY1109489T1 (en)
DE (2) DE60040876D1 (en)
DK (1) DK1473003T3 (en)
ES (2) ES2315598T3 (en)
HK (2) HK1048427B (en)
MX (1) MXPA02002338A (en)
PL (1) PL196988B1 (en)
PT (2) PT1221917E (en)
TR (1) TR200201047T2 (en)
TW (1) TW555575B (en)
WO (1) WO2001028472A1 (en)
ZA (2) ZA200201189B (en)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US20060246145A1 (en) * 2004-04-30 2006-11-02 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid containing microparticles
US20070212397A1 (en) * 2005-09-15 2007-09-13 Roth Daniel B Pharmaceutical delivery device and method for providing ocular treatment
US7589057B2 (en) 2004-04-30 2009-09-15 Allergan, Inc. Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
US20100104654A1 (en) * 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US20100278898A1 (en) * 2004-04-30 2010-11-04 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8277830B2 (en) 2009-01-29 2012-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
US8486052B2 (en) 2001-06-12 2013-07-16 The Johns Hopkins University School Of Medicine Reservoir device for intraocular drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US8900622B1 (en) 2004-04-30 2014-12-02 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8905963B2 (en) 2010-08-05 2014-12-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US20150104491A1 (en) * 2010-04-06 2015-04-16 Allergan, Inc. Sustained-release reservoir implants for intracameral drug delivery
US9326949B2 (en) 2004-04-30 2016-05-03 Allergan, Inc. Method of making oil-in-oil emulsified polymeric implants containing a hypotensive lipid
US9474756B2 (en) 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9492315B2 (en) 2010-08-05 2016-11-15 Forsight Vision4, Inc. Implantable therapeutic device
US9526654B2 (en) 2013-03-28 2016-12-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US9775846B2 (en) 2004-04-30 2017-10-03 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related implants
US9883968B2 (en) 2011-09-16 2018-02-06 Forsight Vision4, Inc. Fluid exchange apparatus and methods
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP3449873A1 (en) * 2006-03-31 2019-03-06 Mati Therapeutics Inc. Drug delivery structures and compositions for nasolacrimal system
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US10258503B2 (en) 2014-07-15 2019-04-16 Forsight Vision4, Inc. Ocular implant delivery device and method
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
US10406029B2 (en) 2001-04-07 2019-09-10 Glaukos Corporation Ocular system with anchoring implant and therapeutic agent
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US10617557B2 (en) 2010-08-05 2020-04-14 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US10874548B2 (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US10959941B2 (en) 2014-05-29 2021-03-30 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US11318043B2 (en) 2016-04-20 2022-05-03 Dose Medical Corporation Bioresorbable ocular drug delivery device
US11419759B2 (en) 2017-11-21 2022-08-23 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
US11432959B2 (en) 2015-11-20 2022-09-06 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010071827A (en) * 1998-07-10 2001-07-31 앤더슨 데릭 제이. Prophylactic treatments of neovascularisation in macular degeneration
BR0010055A (en) 1999-04-26 2002-04-09 Gmp Vision Solutions Inc Bypass device and use thereof
US7943162B2 (en) 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
ATE283013T1 (en) * 1999-10-21 2004-12-15 Alcon Inc MEDICATION DELIVERY DEVICE
US20050119737A1 (en) * 2000-01-12 2005-06-02 Bene Eric A. Ocular implant and methods for making and using same
US7135009B2 (en) 2001-04-07 2006-11-14 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US20020143284A1 (en) * 2001-04-03 2002-10-03 Hosheng Tu Drug-releasing trabecular implant for glaucoma treatment
US6638239B1 (en) 2000-04-14 2003-10-28 Glaukos Corporation Apparatus and method for treating glaucoma
US7708711B2 (en) 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US7867186B2 (en) 2002-04-08 2011-01-11 Glaukos Corporation Devices and methods for treatment of ocular disorders
AR030345A1 (en) * 2000-08-14 2003-08-20 Alcon Inc METHOD OF TREATMENT OF DISORDERS RELATED TO ANGIOGENESIS
EP1345588A2 (en) * 2000-12-29 2003-09-24 Bausch & Lomb Incorporated Sustained release drug delivery devices
US6964781B2 (en) * 2001-01-03 2005-11-15 Bausch & Lomb Incorporated Sustained release drug delivery devices with prefabricated permeable plugs
ES2320533T3 (en) 2001-01-03 2009-05-25 BAUSCH & LOMB INCORPORATED ADMINISTRATION DEVICES OF SUSTAINED RELEASE PHARMACES WITH MULTIPLE AGENTS.
WO2002058667A2 (en) * 2001-01-26 2002-08-01 Bausch & Lomb Incorporated Improved process for the production of sustained release drug delivery devices
US7488303B1 (en) * 2002-09-21 2009-02-10 Glaukos Corporation Ocular implant with anchor and multiple openings
US7678065B2 (en) 2001-05-02 2010-03-16 Glaukos Corporation Implant with intraocular pressure sensor for glaucoma treatment
US7563255B2 (en) * 2001-05-03 2009-07-21 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
AU2002305400A1 (en) 2001-05-03 2002-11-18 Glaukos Corporation Medical device and methods of use for glaucoma treatment
PL204644B1 (en) 2001-07-23 2010-01-29 Alcon Ophthalmic drug delivery device
JP4249611B2 (en) * 2001-07-23 2009-04-02 アルコン,インコーポレイティド Ophthalmic drug delivery device
US7331984B2 (en) 2001-08-28 2008-02-19 Glaukos Corporation Glaucoma stent for treating glaucoma and methods of use
US7749528B2 (en) * 2001-08-29 2010-07-06 Ricardo Azevedo Pontes De Carvalho Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues
PT1420716E (en) * 2001-08-29 2012-11-21 Ricardo A P De Carvalho An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues
US20060034929A1 (en) * 2001-12-27 2006-02-16 Brubaker Michael J Sustained release drug delivery devices with prefabricated permeable plugs
US7186232B1 (en) 2002-03-07 2007-03-06 Glaukoa Corporation Fluid infusion methods for glaucoma treatment
US7951155B2 (en) 2002-03-15 2011-05-31 Glaukos Corporation Combined treatment for cataract and glaucoma treatment
US9301875B2 (en) 2002-04-08 2016-04-05 Glaukos Corporation Ocular disorder treatment implants with multiple opening
WO2003105668A2 (en) * 2002-06-01 2003-12-24 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Injection devices and methods for testing implants and for unimpeded target location testing
US20070265582A1 (en) * 2002-06-12 2007-11-15 University Of Southern California Injection Devices for Unimpeded Target Location Testing
PL375024A1 (en) * 2002-08-05 2005-11-14 Alcon, Inc. Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
DE10238310A1 (en) * 2002-08-21 2004-03-04 Erich Jaeger Gmbh electrode assembly
AU2003279055A1 (en) * 2002-09-29 2004-04-19 Surmodics, Inc. Methods for treatment and/or prevention of retinal disease
WO2004073551A2 (en) * 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
EP1594511A2 (en) * 2003-02-20 2005-11-16 Alcon, Inc. Formulations of glucocorticoids to treat pathologic ocular angiogenesis
WO2004073607A2 (en) * 2003-02-20 2004-09-02 Alcon, Inc. Use of steroids to treat ocular disorders
US20050261668A1 (en) * 2003-03-28 2005-11-24 Bausch & Lomb Incorporated Drug delivery device
US20040236343A1 (en) * 2003-05-23 2004-11-25 Taylor Jon B. Insertion tool for ocular implant and method for using same
KR20060019579A (en) * 2003-06-13 2006-03-03 알콘, 인코퍼레이티드 Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
EP1635842A4 (en) * 2003-06-20 2007-04-04 Alcon Inc Treatment of amd with combination of ingredients
US20040265356A1 (en) * 2003-06-30 2004-12-30 Bausch & Lomb Incorporated Drug delivery device
MXPA05011517A (en) * 2003-07-10 2005-12-12 Alcon Inc Ophthalmic drug delivery device.
WO2005020907A2 (en) 2003-08-26 2005-03-10 Vista Scientific Ocular drug delivery device
US7759472B2 (en) * 2003-08-27 2010-07-20 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
US7585517B2 (en) * 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
US20050136095A1 (en) * 2003-12-22 2005-06-23 Brian Levy Drug delivery device with suture ring
US20050158365A1 (en) * 2003-12-22 2005-07-21 David Watson Drug delivery device with mechanical locking mechanism
US7276050B2 (en) * 2004-03-02 2007-10-02 Alan Franklin Trans-scleral drug delivery method and apparatus
US9549895B2 (en) * 2004-04-23 2017-01-24 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
US20060024350A1 (en) * 2004-06-24 2006-02-02 Varner Signe E Biodegradable ocular devices, methods and systems
US20060110428A1 (en) * 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
WO2006039459A1 (en) * 2004-09-30 2006-04-13 Bausch & Lomb Incorporated Capsule for encasing tablets for surgical insertion into the human body
US20060134162A1 (en) * 2004-12-16 2006-06-22 Larson Christopher W Methods for fabricating a drug delivery device
US20060134176A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
WO2006086750A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
EP1868661A1 (en) * 2005-04-08 2007-12-26 SurModics, Inc. Sustained release implants for subretinal delivery
EP2468318A1 (en) * 2005-07-12 2012-06-27 DMI Biosciences, Inc. Methods and products for treatment of diseases
US20070100199A1 (en) * 2005-11-03 2007-05-03 Lilip Lau Apparatus and method of delivering biomaterial to the heart
WO2007047626A1 (en) * 2005-10-14 2007-04-26 Alcon, Inc. Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
KR101520408B1 (en) 2006-03-23 2015-05-14 산텐 세이야꾸 가부시키가이샤 Formulations and methods for vascular permeability-related diseases or conditions
US20070293807A1 (en) * 2006-05-01 2007-12-20 Lynch Mary G Dual drainage pathway shunt device and method for treating glaucoma
EP2019646A4 (en) * 2006-05-04 2013-12-04 Herbert Kaufman Method, device, and system for delivery of therapeutic agents to the eye
US7981096B2 (en) * 2006-05-12 2011-07-19 David Castillejos Optic nerve head implant and medication delivery system
CN101505696B (en) * 2006-06-21 2012-11-14 庄臣及庄臣视力保护公司 Punctal plugs for the delivery of active agents
US8663303B2 (en) 2010-11-15 2014-03-04 Aquesys, Inc. Methods for deploying an intraocular shunt from a deployment device and into an eye
US8852256B2 (en) 2010-11-15 2014-10-07 Aquesys, Inc. Methods for intraocular shunt placement
US8308701B2 (en) 2010-11-15 2012-11-13 Aquesys, Inc. Methods for deploying intraocular shunts
US10085884B2 (en) 2006-06-30 2018-10-02 Aquesys, Inc. Intraocular devices
US20080108933A1 (en) 2006-06-30 2008-05-08 Dao-Yi Yu Methods, Systems and Apparatus for Relieving Pressure in an Organ
US8721702B2 (en) 2010-11-15 2014-05-13 Aquesys, Inc. Intraocular shunt deployment devices
US20120123316A1 (en) 2010-11-15 2012-05-17 Aquesys, Inc. Intraocular shunts for placement in the intra-tenon's space
JP5748407B2 (en) 2006-11-10 2015-07-15 グローコス コーポレーション Uveal sclera shunt
US20100034808A1 (en) * 2006-11-21 2010-02-11 Toru Nakazawa Compositions and methods for preserving cells of the eye
US20080140024A1 (en) * 2006-12-08 2008-06-12 Yoseph Yaacobi Drug delivery device
MX2009006146A (en) * 2006-12-18 2009-06-19 Alcon Res Ltd Devices and methods for ophthalmic drug delivery.
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
JP5908279B2 (en) * 2008-08-09 2016-04-26 マサチューセッツ インスチテュート オブ テクノロジーMassachusetts Institute Of Technology Implantable drug delivery device and method for treating male genitourinary and surrounding tissues
CN104887388B (en) 2009-06-03 2018-01-09 弗赛特影像5股份有限公司 Anterior segment drug conveys
ES2554688T3 (en) 2009-06-22 2015-12-22 Ampio Pharmaceuticals, Inc. Disease treatment procedure
EP2445350A4 (en) * 2009-06-22 2012-12-26 Dmi Acquisition Corp Methods and products for treatment of diseases
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
AU2011242465B2 (en) 2010-04-23 2017-01-19 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
JP2013526572A (en) 2010-05-17 2013-06-24 アエリエ・ファーマシューティカルズ・インコーポレーテッド Drug delivery device for the delivery of eye treatments
US20120109054A1 (en) * 2010-10-29 2012-05-03 Vista Scientific Llc Devices with an erodible surface for delivering at least one active agent to tissue over a prolonged period of time
WO2012061045A2 (en) 2010-11-01 2012-05-10 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving retinal ganglion cells
US20160256319A1 (en) 2010-11-15 2016-09-08 Aquesys, Inc. Intraocular shunt placement in the suprachoroidal space
EP2670398B1 (en) * 2011-02-04 2017-06-07 TARIS Biomedical LLC Implantable device for controlled release of low solubility drug
US20150005254A1 (en) 2011-06-27 2015-01-01 Massachusetts Eye And Ear Infirmary Methods for treating ocular inflammatory disorders
US9724357B2 (en) 2011-08-15 2017-08-08 Massachusetts Eye & Ear Infirmary Methods for preserving photoreceptor cell viability following retinal detachment
EP4193907A1 (en) 2011-09-13 2023-06-14 Glaukos Corporation Intraocular physiological sensor
US9102105B2 (en) 2011-09-13 2015-08-11 Vista Scientific Llc Method for forming an ocular drug delivery device
JP5989780B2 (en) 2011-09-14 2016-09-07 フォーサイト・ビジョン5・インコーポレイテッドForsight Vision5,Inc. Eye insertion device and method
EP2773341A2 (en) 2011-10-21 2014-09-10 Massachusetts Eye & Ear Infirmary Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders
US8765210B2 (en) 2011-12-08 2014-07-01 Aquesys, Inc. Systems and methods for making gelatin shunts
US9610195B2 (en) 2013-02-27 2017-04-04 Aquesys, Inc. Intraocular shunt implantation methods and devices
US10080682B2 (en) 2011-12-08 2018-09-25 Aquesys, Inc. Intrascleral shunt placement
US8852136B2 (en) * 2011-12-08 2014-10-07 Aquesys, Inc. Methods for placing a shunt into the intra-scleral space
US9808373B2 (en) 2013-06-28 2017-11-07 Aquesys, Inc. Intraocular shunt implantation
EP2708209A1 (en) * 2012-09-13 2014-03-19 AJL Ophthalmic, S.A. Scleral epimacular implant
WO2014066775A1 (en) 2012-10-26 2014-05-01 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
WO2014071054A1 (en) * 2012-11-01 2014-05-08 Poway Retinal Technologies, Llc Retinal repair device and method
EP2934546A4 (en) 2012-12-19 2016-06-22 Ampio Pharmaceuticals Inc Method for treatment of diseases
MX368730B (en) 2013-02-18 2019-10-14 Vegenics Pty Ltd Ligand binding molecules and uses thereof.
US10159600B2 (en) 2013-02-19 2018-12-25 Aquesys, Inc. Adjustable intraocular flow regulation
TW201507749A (en) 2013-03-11 2015-03-01 Sanofi Aventis Deutschland Assembly for a drug delivery device
US9730638B2 (en) 2013-03-13 2017-08-15 Glaukos Corporation Intraocular physiological sensor
US9592151B2 (en) 2013-03-15 2017-03-14 Glaukos Corporation Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye
JP6340673B2 (en) 2013-05-02 2018-06-13 レティナ ファウンデーション オブ ザ サウスウエストRetina Foundation Of The Southwest Double-layered ocular implant
BR112016000546A2 (en) 2013-07-12 2017-11-21 Ophthotech Corp methods to treat or prevent eye conditions
AU2014346559B2 (en) 2013-11-07 2020-07-09 Editas Medicine,Inc. CRISPR-related methods and compositions with governing gRNAs
JP6574780B2 (en) 2013-11-14 2019-09-11 アクエシス, インコーポレイテッド Intraocular shunt inserter
EP3089748A4 (en) 2014-01-02 2017-09-27 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
EP3114227B1 (en) 2014-03-05 2021-07-21 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
WO2015138510A1 (en) 2014-03-10 2015-09-17 Editas Medicine., Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
WO2015148863A2 (en) 2014-03-26 2015-10-01 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
WO2016168141A1 (en) 2015-04-13 2016-10-20 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
CN107690480B (en) 2015-04-24 2022-03-22 爱迪塔斯医药公司 Evaluation of CAS9 molecule/guide RNA molecule complexes
WO2016187426A1 (en) 2015-05-19 2016-11-24 Amorphex Therapeutics Llc A device that delivers a sustained low-dose of a myopia-suppressing drug
UA122570C2 (en) 2015-06-03 2020-12-10 Аквісіс, Інк. Ab externo intraocular shunt placement
AU2016343991B2 (en) 2015-10-30 2022-12-01 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating herpes simplex virus
WO2017165862A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
RU2018142990A (en) 2016-06-02 2020-06-05 Эквисис, Инк. INTERNAL EYE DELIVERY OF MEDICINES
EP3494220A1 (en) 2016-08-02 2019-06-12 Editas Medicine, Inc. Compositions and methods for treating cep290 associated disease
AU2017312499B2 (en) 2016-08-19 2023-02-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration
EP3532616A1 (en) 2016-10-28 2019-09-04 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus
CN110545836A (en) 2017-01-24 2019-12-06 马克雷根有限公司 Treatment of age-related macular degeneration and other ocular diseases with apolipoprotein mimics
CA3054497A1 (en) 2017-03-03 2018-09-07 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
WO2018170184A1 (en) 2017-03-14 2018-09-20 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
ES2945740T3 (en) 2017-05-05 2023-07-06 Univ Pittsburgh Commonwealth Sys Higher Education Matrix-Bound Vesicles (MBV) Ocular Applications
JP2020528082A (en) 2017-07-17 2020-09-17 ロイズマン,キース Topical delivery of therapeutic agents using cell-permeable peptides for the treatment of age-related macular degeneration and other eye diseases
US11246753B2 (en) 2017-11-08 2022-02-15 Aquesys, Inc. Manually adjustable intraocular flow regulation
EP3758736A1 (en) 2018-03-02 2021-01-06 The United States of America, as represented by the Secretary, Department of Health and Human Services Use of il-34 to treat retinal inflammation and neurodegeneration
US10952898B2 (en) 2018-03-09 2021-03-23 Aquesys, Inc. Intraocular shunt inserter
US11135089B2 (en) 2018-03-09 2021-10-05 Aquesys, Inc. Intraocular shunt inserter
EP3931326A1 (en) 2019-02-25 2022-01-05 Editas Medicine, Inc. Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp)
US20230066585A1 (en) 2020-01-17 2023-03-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Gene therapy for treatment of crx-autosomal dominant retinopathies
JP2023532134A (en) 2020-07-02 2023-07-26 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ Cyclic compound for use in treating retinal degeneration
WO2022221741A1 (en) 2021-04-16 2022-10-20 Editas Medicine, Inc. Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp)
CN115737892A (en) * 2022-11-21 2023-03-07 诺莱生物医学科技有限公司 Elastic dressing carrying repair matrix and preparation method thereof

Citations (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) * 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3828777A (en) * 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
US4014725A (en) * 1975-03-27 1977-03-29 Union Carbide Corporation Method of making carbon cloth from pitch based fiber
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4300557A (en) * 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4946450A (en) * 1989-04-18 1990-08-07 Biosource Genetics Corporation Glucan/collagen therapeutic eye shields
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5147647A (en) * 1986-10-02 1992-09-15 Sohrab Darougar Ocular insert for the fornix
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US5322691A (en) * 1986-10-02 1994-06-21 Sohrab Darougar Ocular insert with anchoring protrusions
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5403901A (en) * 1990-11-07 1995-04-04 Nestle S.A. Flexible, high refractive index polymers
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5466466A (en) * 1989-02-18 1995-11-14 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Therapeutic system for the retarded and controlled transdermal or transmucous administration of active substrates II
US5516522A (en) * 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5632984A (en) * 1993-07-22 1997-05-27 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5679666A (en) * 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
US5710165A (en) * 1994-07-06 1998-01-20 Synthelabo Use of polyamine antagonists for the treatment of glaucoma
US5725493A (en) * 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US5743274A (en) * 1996-03-18 1998-04-28 Peyman; Gholam A. Macular bandage for use in the treatment of subretinal neovascular members
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5797898A (en) * 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US5824073A (en) * 1996-03-18 1998-10-20 Peyman; Gholam A. Macular indentor for use in the treatment of subretinal neovascular membranes
US5836935A (en) * 1994-11-10 1998-11-17 Ashton; Paul Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
US5883108A (en) * 1995-11-17 1999-03-16 Alcon Laboratories, Inc. Combination therapy for treating glaucoma
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US5916584A (en) * 1994-10-25 1999-06-29 Daratech Proprietary Limited Controlled release container with core and outer shell
US6074661A (en) * 1997-08-11 2000-06-13 Allergan Sales, Inc. Sterile bioerodible occular implant device with a retinoid for improved biocompatability
US6120460A (en) * 1996-09-04 2000-09-19 Abreu; Marcio Marc Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions
US6146366A (en) * 1998-11-03 2000-11-14 Ras Holding Corp Device for the treatment of macular degeneration and other eye disorders
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6413540B1 (en) * 1999-10-21 2002-07-02 Alcon Universal Ltd. Drug delivery device

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4759746A (en) * 1987-05-14 1988-07-26 Straus Jeffrey G Retro-bulbar needle
DE4022553A1 (en) * 1990-07-16 1992-01-23 Hund Helmut Gmbh Medical contact lens - with recess contg. therapeutically or diagnostically active substance
FR2690846B1 (en) 1992-05-05 1995-07-07 Aiache Jean Marc GALENIC FORM FOR EYE ADMINISTRATION AND METHOD OF PREPARATION.
WO1994005257A1 (en) 1992-09-08 1994-03-17 Allergan, Inc. Sustained release of ophthalmic drugs from a soluble polymer drug delivery vehicle
AU704591B2 (en) 1994-04-04 1999-04-29 William R. Freeman Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
US5466233A (en) 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
CN2219115Y (en) * 1994-08-31 1996-02-07 程康 Pulse medicine therapeutic apparatus for myopia
CN1283324C (en) 1995-05-14 2006-11-08 奥普通诺尔有限公司 Intraocular implant, delivery device, and method of implantation
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
JP3309175B2 (en) 1996-03-25 2002-07-29 参天製薬株式会社 Scleral plug containing proteinaceous drug
ZA9710342B (en) * 1996-11-25 1998-06-10 Alza Corp Directional drug delivery stent and method of use.
EP0973499B1 (en) * 1997-03-31 2003-08-06 Alza Corporation Diffusional implantable delivery system
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
ATE365550T1 (en) 1998-03-13 2007-07-15 Univ Johns Hopkins Med USE OF A PROTEIN KINASE INHIBITOR SUCH AS GENISTEIN IN THE TREATMENT OF DIABETIC RETINOPATHY
DE19847192A1 (en) 1998-10-13 2000-04-27 Wella Ag Colorant for fibers, especially human hair, contains 4-nitrophenyl-N-heterocyclic, -cycloalkane, -alkoxyalkane or -amine compound
US6399655B1 (en) 1998-12-22 2002-06-04 Johns Hopkins University, School Of Medicine Method for the prophylactic treatment of cataracts

Patent Citations (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) * 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3828777A (en) * 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
US4014725A (en) * 1975-03-27 1977-03-29 Union Carbide Corporation Method of making carbon cloth from pitch based fiber
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4300557A (en) * 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US5147647A (en) * 1986-10-02 1992-09-15 Sohrab Darougar Ocular insert for the fornix
US5322691A (en) * 1986-10-02 1994-06-21 Sohrab Darougar Ocular insert with anchoring protrusions
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5466466A (en) * 1989-02-18 1995-11-14 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Therapeutic system for the retarded and controlled transdermal or transmucous administration of active substrates II
US4946450A (en) * 1989-04-18 1990-08-07 Biosource Genetics Corporation Glucan/collagen therapeutic eye shields
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5403901A (en) * 1990-11-07 1995-04-04 Nestle S.A. Flexible, high refractive index polymers
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5679666A (en) * 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
US5300114A (en) * 1992-05-04 1994-04-05 Allergan, Inc. Subconjunctival implants for ocular drug delivery
US5476511A (en) * 1992-05-04 1995-12-19 Allergan, Inc. Subconjunctival implants for ocular drug delivery
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US5632984A (en) * 1993-07-22 1997-05-27 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5766242A (en) * 1993-11-15 1998-06-16 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5824072A (en) * 1993-11-15 1998-10-20 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5516522A (en) * 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5710165A (en) * 1994-07-06 1998-01-20 Synthelabo Use of polyamine antagonists for the treatment of glaucoma
US5916584A (en) * 1994-10-25 1999-06-29 Daratech Proprietary Limited Controlled release container with core and outer shell
US5836935A (en) * 1994-11-10 1998-11-17 Ashton; Paul Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
US5830173A (en) * 1994-12-12 1998-11-03 Avery; Robert Logan Intravitreal medicine delivery
US5725493A (en) * 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US6001386A (en) * 1995-09-27 1999-12-14 University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5883108A (en) * 1995-11-17 1999-03-16 Alcon Laboratories, Inc. Combination therapy for treating glaucoma
US6126687A (en) * 1996-03-18 2000-10-03 Peyman; Gholam A. Macular bandage for use in the treatment of subretinal neovascular membranes
US5743274A (en) * 1996-03-18 1998-04-28 Peyman; Gholam A. Macular bandage for use in the treatment of subretinal neovascular members
US5824073A (en) * 1996-03-18 1998-10-20 Peyman; Gholam A. Macular indentor for use in the treatment of subretinal neovascular membranes
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US5797898A (en) * 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US6120460A (en) * 1996-09-04 2000-09-19 Abreu; Marcio Marc Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions
US6110485A (en) * 1997-08-11 2000-08-29 Allergan Sales, Inc. Sterile bioerodible implant device with a retinoid for improved biocompatability
US6074661A (en) * 1997-08-11 2000-06-13 Allergan Sales, Inc. Sterile bioerodible occular implant device with a retinoid for improved biocompatability
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6146366A (en) * 1998-11-03 2000-11-14 Ras Holding Corp Device for the treatment of macular degeneration and other eye disorders
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6413540B1 (en) * 1999-10-21 2002-07-02 Alcon Universal Ltd. Drug delivery device
US6808719B2 (en) * 1999-10-21 2004-10-26 Alcon, Inc. Drug delivery device

Cited By (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10406029B2 (en) 2001-04-07 2019-09-10 Glaukos Corporation Ocular system with anchoring implant and therapeutic agent
US10470924B2 (en) 2001-06-12 2019-11-12 The Johns Hopkins University Reservoir device for intraocular drug delivery
US9180046B2 (en) 2001-06-12 2015-11-10 The Johns Hopkins University School Of Medicine Reservoir device for intraocular drug delivery
US9522082B2 (en) 2001-06-12 2016-12-20 The Johns Hopkins University Reservoir device for intraocular drug delivery
US8486052B2 (en) 2001-06-12 2013-07-16 The Johns Hopkins University School Of Medicine Reservoir device for intraocular drug delivery
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US10328086B2 (en) 2004-04-30 2019-06-25 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US20100278898A1 (en) * 2004-04-30 2010-11-04 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US9669039B2 (en) 2004-04-30 2017-06-06 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US10406168B2 (en) 2004-04-30 2019-09-10 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US7589057B2 (en) 2004-04-30 2009-09-15 Allergan, Inc. Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
US9707238B2 (en) 2004-04-30 2017-07-18 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US10398707B2 (en) 2004-04-30 2019-09-03 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related implants
US8900622B1 (en) 2004-04-30 2014-12-02 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US10864218B2 (en) 2004-04-30 2020-12-15 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US9750751B2 (en) 2004-04-30 2017-09-05 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US10064872B2 (en) 2004-04-30 2018-09-04 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US9775846B2 (en) 2004-04-30 2017-10-03 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related implants
US9101583B2 (en) 2004-04-30 2015-08-11 Allergan, Inc. Microparticles manufactured in an oil-in-water process comprising a prostamide
US20060246145A1 (en) * 2004-04-30 2006-11-02 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid containing microparticles
US9326949B2 (en) 2004-04-30 2016-05-03 Allergan, Inc. Method of making oil-in-oil emulsified polymeric implants containing a hypotensive lipid
US9393223B2 (en) 2004-04-30 2016-07-19 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20070212397A1 (en) * 2005-09-15 2007-09-13 Roth Daniel B Pharmaceutical delivery device and method for providing ocular treatment
EP3449873A1 (en) * 2006-03-31 2019-03-06 Mati Therapeutics Inc. Drug delivery structures and compositions for nasolacrimal system
US20100104654A1 (en) * 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US10813788B2 (en) 2009-01-29 2020-10-27 Forsight Vision4, Inc. Implantable therapeutic device
US8277830B2 (en) 2009-01-29 2012-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
US10656152B2 (en) 2009-01-29 2020-05-19 Forsight Vision4, Inc. Posterior segment drug delivery
US8298578B2 (en) 2009-01-29 2012-10-30 Forsight Vision4, Inc. Posterior segment drug delivery
US9417238B2 (en) 2009-01-29 2016-08-16 Forsight Vision4, Inc. Posterior segment drug delivery
US9066779B2 (en) 2009-01-29 2015-06-30 Forsight Vision4, Inc. Implantable therapeutic device
US9851351B2 (en) 2009-01-29 2017-12-26 Forsight Vision4, Inc. Posterior segment drug delivery
US8808727B2 (en) 2009-01-29 2014-08-19 Forsight Vision4, Inc. Posterior segment drug delivery
US8399006B2 (en) 2009-01-29 2013-03-19 Forsight Vision4, Inc. Posterior segment drug delivery
US11642310B2 (en) 2009-01-29 2023-05-09 Forsight Vision4, Inc. Posterior segment drug delivery
US8795712B2 (en) 2009-01-29 2014-08-05 Forsight Vision4, Inc. Posterior segment drug delivery
US11426306B2 (en) 2009-05-18 2022-08-30 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
US20150104491A1 (en) * 2010-04-06 2015-04-16 Allergan, Inc. Sustained-release reservoir implants for intracameral drug delivery
US9033911B2 (en) 2010-08-05 2015-05-19 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US11786396B2 (en) 2010-08-05 2023-10-17 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US10265215B2 (en) 2010-08-05 2019-04-23 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US8905963B2 (en) 2010-08-05 2014-12-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US9492315B2 (en) 2010-08-05 2016-11-15 Forsight Vision4, Inc. Implantable therapeutic device
US10617557B2 (en) 2010-08-05 2020-04-14 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US9861521B2 (en) 2010-08-05 2018-01-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US11679027B2 (en) 2010-08-05 2023-06-20 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US11065151B2 (en) 2010-11-19 2021-07-20 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US10874548B2 (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US11813196B2 (en) 2011-06-28 2023-11-14 Forsight Vision4, Inc. Diagnostic methods and apparatus
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
US9883968B2 (en) 2011-09-16 2018-02-06 Forsight Vision4, Inc. Fluid exchange apparatus and methods
US10653554B2 (en) 2011-09-16 2020-05-19 Forsight Vision4, Inc. Fluid exchange apparatus and methods
US10603209B2 (en) 2012-02-03 2020-03-31 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US11253394B2 (en) 2013-03-15 2022-02-22 Dose Medical Corporation Controlled drug delivery ocular implants and methods of using same
US9526654B2 (en) 2013-03-28 2016-12-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US10398593B2 (en) 2013-03-28 2019-09-03 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US11510810B2 (en) 2013-03-28 2022-11-29 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US10959941B2 (en) 2014-05-29 2021-03-30 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US11337853B2 (en) 2014-07-15 2022-05-24 Forsight Vision4, Inc. Ocular implant delivery device and method
US10258503B2 (en) 2014-07-15 2019-04-16 Forsight Vision4, Inc. Ocular implant delivery device and method
US9895369B2 (en) 2014-08-08 2018-02-20 Forsight Vision4, Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US10765677B2 (en) 2014-08-08 2020-09-08 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9474756B2 (en) 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US10363255B2 (en) 2014-08-08 2019-07-30 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US11110001B2 (en) 2014-11-10 2021-09-07 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US11432959B2 (en) 2015-11-20 2022-09-06 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices
US11318043B2 (en) 2016-04-20 2022-05-03 Dose Medical Corporation Bioresorbable ocular drug delivery device
US11419759B2 (en) 2017-11-21 2022-08-23 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use

Also Published As

Publication number Publication date
BR0014929A (en) 2002-10-01
HK1048427A1 (en) 2003-04-04
PL196988B1 (en) 2008-02-29
PL355263A1 (en) 2004-04-05
US20020197298A1 (en) 2002-12-26
AR039132A2 (en) 2005-02-09
CA2383499A1 (en) 2001-04-26
KR20020059630A (en) 2002-07-13
EP1473003B1 (en) 2008-11-19
DE60040876D1 (en) 2009-01-02
TR200201047T2 (en) 2002-07-22
HK1048427B (en) 2005-04-22
HK1072177A1 (en) 2005-08-19
ATE414494T1 (en) 2008-12-15
PT1221917E (en) 2005-04-29
CA2383499C (en) 2009-11-24
TW555575B (en) 2003-10-01
US6808719B2 (en) 2004-10-26
AR026165A1 (en) 2003-01-29
CN1292721C (en) 2007-01-03
KR100732262B1 (en) 2007-06-25
EP1473003A3 (en) 2005-12-14
CY1109489T1 (en) 2014-08-13
AU2004200908A1 (en) 2004-04-01
CN1630497A (en) 2005-06-22
DE60016271D1 (en) 2004-12-30
AU2004200908B2 (en) 2005-06-23
JP4837861B2 (en) 2011-12-14
AU7373300A (en) 2001-04-30
ZA200201189B (en) 2003-02-12
EP1473003A2 (en) 2004-11-03
MXPA02002338A (en) 2002-07-30
ATE283013T1 (en) 2004-12-15
AU768400B2 (en) 2003-12-11
PT1473003E (en) 2008-12-26
DK1473003T3 (en) 2009-03-16
EP1221917B1 (en) 2004-11-24
EP1221917A1 (en) 2002-07-17
AR039131A2 (en) 2005-02-09
DE60016271T2 (en) 2005-12-01
ZA200201188B (en) 2003-04-30
BR0014929B1 (en) 2009-01-13
ES2315598T3 (en) 2009-04-01
US6413540B1 (en) 2002-07-02
ES2231257T3 (en) 2005-05-16
JP2003515528A (en) 2003-05-07
WO2001028472A1 (en) 2001-04-26

Similar Documents

Publication Publication Date Title
US6808719B2 (en) Drug delivery device
US7943162B2 (en) Drug delivery device
US6986900B2 (en) Ophthalmic drug delivery device
US6669950B2 (en) Ophthalmic drug delivery device
US7094226B2 (en) Ophthalmic drug delivery device
AU2002319606A1 (en) Ophthalmic drug delivery device

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALCON, INC., SWITZERLAND

Free format text: CHANGE OF NAME;ASSIGNOR:ALCON UNIVERSAL LTD.;REEL/FRAME:016963/0321

Effective date: 20020211

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION